Participants Flow



GuARD study: Demographics at screening - Analysis population (mITT)

	Vehicle gel (N=8)	4.7% GR1014-CG (N=8)	2.4% GR1014-CG (N=12)
Age (years), n	8	8	12
Mean (SD)	60.5 (5.5)	65.5 (10.3)	66.8 (11.1)
Skin Phototype (Fitzpatrick scale), n (%)	8	8	12
Type I (score 0–6)	0 (0.0)	2 (25.0)	1 (8.3)
Type II (score 7–13)	4 (50.0)	0 (0.0)	4 (33.3)
Type III (score 14–20)	4 (50.0)	5 (62.5)	4 (33.3)
Type IV (score 21–27)	0 (0.0)	0 (0.0)	2 (16.7)
Type V (score 28–34)	0 (0.0)	0 (0.0)	0 (0.0)
Type VI (score 35–36)	0 (0.0)	1 (12.5)	1 (8.3)
ECOG score, n (%)	8	8	12
0	8 (100.0)	8 (100.0)	11 (91.7)
1	0 (0.0)	0 (0.0)	1 (8.3)
Bra Cup Size, n (%)	8	8	12
< D	5 (62.5)	4 (50.0)	5 (41.7)
≥ D	3 (37.5)	4 (50.0)	7 (58.3)
Smoking status, n (%)	8	8	12
Non smoker	5 (62.5)	6 (75.0)	7 (58.3)
Current smoker	2 (25.0)	0 (0.0)	2 (16.7)
Ex-smoker	1 (12.5)	2 (25.0)	3 (25.0)
Childbearing potential, n (%)	8	8	12
Yes	1 (12.5)	1 (12.5)	2 (16.7)
No	7 (87.5)	7 (87.5)	10 (83.3)
BMI (kg/m^2)*, n	8	8	12
Mean (SD)	26.3 (3.6)	28.8 (5.1)	26.2 (3.1)
Total body surface area (TBSA - m^2)**, n	8	8	12
Mean (SD)	1.8 (0.1)	1.8 (0.2)	1.7 (0.2)
Cancer stage, n (%)	7	7	12
Stage IA	6 (85.7)	6 (85.7)	9 (75.0)
Stage IB	0 (0.0)	0 (0.0)	0 (0.0)
Stage IIA	1 (14.3)	1 (14.3)	3 (25.0)
Missing	1	1	0
Histological type, n (%)	8	8	12
Infiltrating ductal carcinoma	3 (37.5)	3 (37.5)	4 (33.3)
Infiltrating lobular carcinoma	1 (12.5)	0 (0.0)	3 (25.0)
Ductal Carcinoma in Situ (DCIS)	4 (50.0)	4 (50.0)	2 (16.7)
Other	0 (0.0)	1 (12.5)	3 (25.0)
Grade, n (%)	7	7	11
Grade 1	3 (42.9)	2 (28.6)	1 (9.1)

GuARD study: Demographics at screening - Analysis population (mITT)

	Vehicle gel (N=8)	4.7% GR1014-CG (N=8)	2.4% GR1014-CG (N=12)
Grade 2	3 (42.9)	5 (71.4)	8 (72.7)
Grade 3	1 (14.3)	0 (0.0)	2 (18.2)
Missing	1	1	1
Hormone Receptor Status			
ER status, n (%)	6	8	12
Positive	6 (100.0)	8 (100.0)	10 (83.3)
Negative	0 (0.0)	0 (0.0)	2 (16.7)
Missing	2	0	0
PR status, n (%)	6	8	11
Positive	5 (83.3)	7 (87.5)	7 (63.6)
Negative	1 (16.7)	1 (12.5)	4 (36.4)
Missing	2	0	1
Subtype, n (%)	6	8	11
HER2+	0 (0.0)	3 (37.5)	0 (0.0)
HER2- with ER+ or PR+	6 (100.0)	5 (62.5)	9 (81.8)
HER2- and ER- and PR-	0 (0.0)	0 (0.0)	2 (18.2)
Missing	2	0	1

n: number of subjects
Percentages are based on the number of patients that contribute to the analysis (N).
*BMI (kg/m^2) = Weight(kg)/Height$(m)^2$
**TBSA (m^2) = 0.007184 x Weight(kg) 0.425 x Height(cm) 0.725
Note: Grade 1: well differentiated; Grade 2: moderately differentiated; Grade 3: poorly differentiated

GuARD study: Summary Table of Outcome Measures by Treatment Group (mITT population)

Endpoint	Vehicle gel (N=8)	4.7% GR1014-CG (N=8)	2.4% GR1014-CG (N=12)
	number of participants (%)		
PRIMARY ENDPOINT			
No Radiation Dermatitis (Grade = 0) between the first RT session and 4 weeks after the last one	3 (37.5)	0 (0.0)	3 (25.0)
SECONDARY ENDPOINTS			
Radiation Dermatitis Grade ≥2 between the first RT session and 4 weeks after the last one	0 (0.0)	1 (12.5)	2 (16.7)
Maximum Grade of Radiation Dermatitis between the first RT session and 4 weeks after the last one			
Grade=0 (No Dermatitis)	3 (37.5)	0 (0.0)	3 (25.0)
Grade=1	5 (62.5)	7 (87.5)	7 (58.3)
Grade=2	0 (0.0)	1 (12.5)	2 (16.7)
No Radiation Dermatitis (Grade 0) at Visit 10	5 (71.4)	5 (62.5)	9 (75.0)
Missing	1	0	0

n: number of subjects, CI: Confidence interval
Percentages are based on the number of participants that contribute to the analysis (N).

GuARD study: Serious TEAE - Analysis population (SAF)

	Vehicle gel (N=8)		4.7% GR1014-CG (N=8)		2.4% GR1014-CG (N=12)	
	TESAE[a]	n (%)[b]	TESAE[a]	n (%)[b]	TESAE[a]	n (%)[b]
Participants with at least one serious TEAE, n (%)	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)

[a] TESAE: number of serious treatment emergent adverse events.
[b] n: number of patients with at least one TESAE. If a subject experienced more than one TESAE in a category, the subject was counted only once in that category.
Percentages are based on the number of patients that contribute to the analysis (N).

GuARD study: Description of TEAE - Analysis population (SAF)

	Vehicle gel (N=8)		4.7% GR1014-CG (N=8)		2.4% GR1014-CG (N=12)	
	n (%)[a]	TEAE[b]	n (%)[a]	TEAE[b]	n (%)[a]	TEAE[b]
Severity CTCAE Grade						
Grade 1: Mild	8 (100.0)	23	8 (100.0)	32	11 (100.0)	42
Grade 2: Moderate	5 (62.5)	6	4 (50.0)	10	7 (63.6)	9

[a] n: number of patients with at least one treatment emergent adverse event
[b] TEAE: number of treatment emergent adverse events.
Percentages are based on the number of patients that contribute to the analysis (N).
A same patient can have more than one treatment emergent adverse event.

GuARD study: TEAE according to System Organ Class and Preferred Term - Analysis population (SAF)

	Vehicle gel (N=8)		4.7% GR1014-CG (N=8)		2.4% GR1014-CG (N=12)	
	n (%)[a]	TEAE[b]	n (%)[a]	TEAE[b]	n (%)[a]	TEAE[b]
Participants with at least one TEAE, n (%)	29	8 (100.0)	42	8 (100.0)	51	11 (91.7)
Eye disorders , N (%)	1	1 (12.5)	0	0 (0.0)	0	0 (0.0)
Visual impairment	1	1 (12.5)	0	0 (0.0)	0	0 (0.0)
Gastrointestinal disorders, N (%)	0	0 (0.0)	0	0 (0.0)	2	2 (16.7)
Nausea	0	0 (0.0)	0	0 (0.0)	2	2 (16.7)
General disorders and administration site conditions, N (%)	7	4 (50.0)	7	5 (62.5)	13	7 (58.3)
Fatigue	3	2 (25.0)	2	2 (25.0)	6	5 (41.7)
Epithelitis	2	2 (25.0)	2	2 (25.0)	3	3 (25.0)
Asthenia	1	1 (12.5)	2	1 (12.5)	3	3 (25.0)
Axillary pain	1	1 (12.5)	0	0 (0.0)	0	0 (0.0)
Feeling cold	0	0 (0.0)	0	0 (0.0)	1	1 (8.3)
Induration	0	0 (0.0)	1	1 (12.5)	0	0 (0.0)
Infections and infestations, N (%)	0	0 (0.0)	1	1 (12.5)	1	1 (8.3)
Influenza	0	0 (0.0)	1	1 (12.5)	1	1 (8.3)

GuARD study: TEAE according to System Organ Class and Preferred Term - Analysis population (SAF)

	Vehicle gel (N=8)		4.7% GR1014-CG (N=8)		2.4% GR1014-CG (N=12)	
	n (%)[a]	TEAE[b]	n (%)[a]	TEAE[b]	n (%)[a]	TEAE[b]
Injury, poisoning and procedural complications, N (%)	5	4 (50.0)	7	6 (75.0)	12	8 (66.7)
Radiation skin injury	4	4 (50.0)	7	6 (75.0)	11	8 (66.7)
Radiation induced fatigue	1	1 (12.5)	0	0 (0.0)	0	0 (0.0)
Thermal burn	0	0 (0.0)	0	0 (0.0)	1	1 (8.3)
Metabolism and nutrition disorders, N (%)	1	1 (12.5)	1	1 (12.5)	1	1 (8.3)
Vitamin D deficiency	1	1 (12.5)	1	1 (12.5)	0	0 (0.0)
Decreased appetite	0	0 (0.0)	0	0 (0.0)	1	1 (8.3)
Musculoskeletal and connective tissue disorders, N (%)	1	1 (12.5)	2	1 (12.5)	4	4 (33.3)
Arthralgia	0	0 (0.0)	2	1 (12.5)	2	2 (16.7)
Bone pain	0	0 (0.0)	0	0 (0.0)	1	1 (8.3)
Osteoarthritis	0	0 (0.0)	0	0 (0.0)	1	1 (8.3)
Osteoporosis	1	1 (12.5)	0	0 (0.0)	0	0 (0.0)
Nervous system disorders, N (%)	1	1 (12.5)	0	0 (0.0)	0	0 (0.0)
Headache	1	1 (12.5)	0	0 (0.0)	0	0 (0.0)
Reproductive system and breast disorders, N (%)	7	5 (62.5)	3	2 (25.0)	8	4 (33.3)
Breast fibrosis	2	2 (25.0)	1	1 (12.5)	2	2 (16.7)
Breast oedema	3	2 (25.0)	1	1 (12.5)	2	2 (16.7)
Breast pain	2	2 (25.0)	1	1 (12.5)	0	0 (0.0)
Breast induration	0	0 (0.0)	0	0 (0.0)	1	1 (8.3)
Endometrial thickening	0	0 (0.0)	0	0 (0.0)	1	1 (8.3)
Menstruation irregular	0	0 (0.0)	0	0 (0.0)	1	1 (8.3)
Nipple pain	0	0 (0.0)	0	0 (0.0)	1	1 (8.3)
Respiratory, thoracic and mediastinal disorders, N (%)	0	0 (0.0)	1	1 (12.5)	1	1 (8.3)
Dyspnoea exertional	0	0 (0.0)	0	0 (0.0)	1	1 (8.3)
Oropharyngeal pain	0	0 (0.0)	1	1 (12.5)	0	0 (0.0)
Skin and subcutaneous tissue disorders, N (%)	4	4 (50.0)	18	7 (87.5)	9	6 (50.0)
Pruritus	1	1 (12.5)	7	5 (62.5)	2	2 (16.7)
Erythema	1	1 (12.5)	5	4 (50.0)	2	2 (16.7)
Skin hyperpigmentation	1	1 (12.5)	1	1 (12.5)	2	2 (16.7)
Rash maculo-papular	0	0 (0.0)	2	2 (25.0)	1	1 (8.3)
Telangiectasia	0	0 (0.0)	2	2 (25.0)	1	1 (8.3)
Macule	0	0 (0.0)	1	1 (12.5)	0	0 (0.0)
Rash	1	1 (12.5)	0	0 (0.0)	0	0 (0.0)
Rash papular	0	0 (0.0)	0	0 (0.0)	1	1 (8.3)
Vascular disorders, N (%)	2	2 (25.0)	2	2 (25.0)	0	0 (0.0)
Hypertension	2	2 (25.0)	1	1 (12.5)	0	0 (0.0)
Hot flush	0	0 (0.0)	1	1 (12.5)	0	0 (0.0)

[a] TEAE: number of treatment emergent adverse events.
[b] n: number of patients with at least one TEAE. If a subject experienced more than one TEAE in a category, the subject was counted only once in that category.
Percentages are based on the number of patients that contribute to the analysis (N).

GuARD Study: AESI according to System Organ Class and Preferred Term - Analysis population (SAF)

	Vehicle gel (N=8)		4.7% GR1014-CG (N=8)		2.4% GR1014-CG (N=12)	
	AESI[a]	**n (%)[b]**	**AESI[a]**	**n (%)[b]**	**AESI[a]**	**n (%)[b]**
Participants with at least one AESI, n (%)	2	2 (25.0)		0 (0.0)	2	2 (16.7)
Gastrointestinal disorders, N (%)	0	0 (0.0)	0	0 (0.0)	2	2 (16.7)
Nausea	0	0 (0.0)	0	0 (0.0)	2	2 (16.7)
Reproductive system and breast disorders, N (%)	1	1 (12.5)	0	0 (0.0)	0	0 (0.0)
Breast oedema	1	1 (12.5)	0	0 (0.0)	0	0 (0.0)
Skin and subcutaneous tissue disorders, N (%)	1	1 (12.5)	0	0 (0.0)	0	0 (0.0)
Rash	1	1 (12.5)	0	0 (0.0)	0	0 (0.0)

AESI: adverse event of special interest
[a] AESI: number of AESI
[b] n: number of patients with at least one AESI. If a subject experienced more than one AESI in a category, the subject was counted only once in that category.
Percentages are based on the number of patients that contribute to the analysis (N).